作者@article {Lu1801562 = {Lu,小君,钟,华和楚,专业和张,胡雪岩和李,荣和太阳,世纪佳缘,钟,Runbo和阳,Yuqin阿拉姆,默罕默德·沙阿和卢,余庆、徐,王健林和张,艘Yanwei和吴,小君和李,小薇和赵,小东和李,凯和陆,李明和汉族,宝会},题目= {Role of anlotinib induced CCL2 decrease in anti-angiogenesis and response prediction for non - small cell lung cancer therapy}， volume = {53}， number = {3}， position -id = {1801562}， year = {2019}， doi = {10.1183/13993003.01562-2018}， publisher = {E188bet官网地址uropean Respiratory Society}，在临床试验中，Anlotinib已被证明能够有效延长难治性晚期非小细胞肺癌(NSCLC)患者的无进展生存期(PFS)和总生存期(OS)。然而，安洛替尼的潜在分子机制和预测生物标志物仍不清楚。方法回顾性分析294例非小细胞肺癌患者接受安洛替尼治疗，筛选安洛替尼反应患者的潜在生物标志物。通过转录组和功能分析来了解安洛替尼的抗肿瘤分子机制。分析血清CCL2水平的变化，以检测有应答者和无应答者之间安洛替尼应答的相关性。结果Anlotinib治疗有利于驱动基因阳性突变的NSCLC患者延长OS，特别是上皮生长因子受体(EGFR)T790M突变的NSCLC患者。此外，anlotinib通过抑制CCL2抑制nci - h1975衍生的异种移植模型中的血管生成。最后，anlotinib诱导的血清CCL2水平下降与难治性晚期NSCLC患者的PFS和OS获益相关。Conclusions Our study reports a novel anti-angiogenesis mechanism of anlotinib via inhibiting CCL2 in an NCI-H1975-derived xenograft model and suggests that changes in serum CCL2 levels may be used to monitor and predict clinical outcomes in anlotinib-administered refractory advanced NSCLC patients using third-line therapy or beyond.The underlying molecular mechanisms and predictive biomarkers of anlotinib benefitting NSCLC patients are still unclear. In this study, anlotinib-induced CCL2 decrease contributes to a novel insight for its anti-angiogenesis mechanism and responsive prediction. http://ow.ly/YZL930mXlfV}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/53/3/1801562}, eprint = {//www.qdcxjkg.com/content/53/3/1801562.full.pdf}, journal = {European Respiratory Journal} }